Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)
Por um escritor misterioso
Descrição
Updates on novel pharmacotherapeutics for the treatment of
MGAT2 inhibitor decreases liver fibrosis and inflammation in
Frontiers Baicalein Prevents Fructose-Induced Hepatic Steatosis
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the
Targeting diacylglycerol acyltransferase 2 for the treatment of
MGAT2 inhibitor decreases liver fibrosis and inflammation in
NASH Target Development Service for DAG O-Acyltransferase (DGAT
Targeting diacylglycerol acyltransferase 2 for the treatment of
Beyond triglyceride synthesis: the dynamic functional roles of
Nonalcoholic Fatty Liver Disease: The Overlooked Complication of
Novel antisense inhibition of diacylglycerol O-acyltransferase 2
MGAT2 inhibitor decreases liver fibrosis and inflammation in
Beyond triglyceride synthesis: the dynamic functional roles of
Efficacy and safety of an orally administered DGAT2 inhibitor
MGAT2 inhibitor decreases liver fibrosis and inflammation in
de
por adulto (o preço varia de acordo com o tamanho do grupo)
